Assessing Generic & Biosimilar Manufacturing in North America & the Potential Opportunity for the CaliBaja Region

July 16, 2024 | 8:30-10:30 am
Institute of the Americas complex (UC San Diego campus)

*This event is free of charge; prior registration is required.

In recent years, the United States has experienced shortages of many essential medicines, putting at risk the stability of its healthcare systems and ability to meet the priority health care needs of its population. Over 90% of medicines consumed by Americans are generic drugs and biosimilars. 

The U.S. has become over-reliant on lower cost overseas sources for much of the active pharmaceutical ingredients (APIs) and key starting materials (KSMs) required to make many generic and essential drugs. While the United States is a world leader in developing and marketing patented branded prescription drugs, a significant portion of America’s generic drugs are sourced from overseas, with a large percentage also coming from China and India. This dependence poses supply chain risks and national security concerns.

As the United States looks to strengthen and make its pharmaceutical supply chain more resilient, the CaliBaja region could play a valuable role given San Diego’s strong life science ecosystem and Baja California’s lower cost of manufacturing and talented STEM labor force.   

Given emerging needs for essential medicines in North America, the forum will examine opportunities for future generic and biosimilar manufacturing in Mexico, with a special emphasis on Baja California’s potential cross-border nexus with San Diego.

Program

8:30am Registration

Welcoming Remarks

  • Tad Parzen, President & CEO, Burnham Center for Community Advancement & Board Member, Institute of the Americas
  • Richard Kiy, President & CEO, Institute of the Americas
  • Emily Desai, Senior Deputy Director of Global & Strategic Program Planning & External Affairs for California Governor’s Office of Business & Economic Development (Video message)

Keynote Address

  • U.S. Congressman Scott Peters (D-CA), Co-Founder and Co-Chair, Congressional Life Sciences Caucus

Panel Discussion | Strengthening U.S.-Mexico Quality Pharmaceutical Supply Chains & the Potential Opportunity for the CaliBaja Region

  • Andrew Rudman, former Director, Mexico Institute, Wilson Center and co-author, Strengthening U.S.-Mexico Quality Pharmaceutical Supply Chains
  • John Fry, Senior Advisor, Institute of the Americas
  • Juan de Villafranca, President & CEO, AMELAF
  • Astrea Ocampo, Director General,  Grupo Neolpharma
    Moderator:  Shane Christensen, Diplomatic Fellow, Institute of the Americas

Questions & Answers

10:30am Closing

This program and research were made possible thanks to the generous support of:

The Burnham Foundation
Steve Williams
Bill Koman

Alumbra Innovations Foundation
California Governor’s Office of Business & Economic Development